Navigation Links
QuantaLife Announces Launch of Droplet Digital™ PCR System
Date:11/2/2010

WASHINGTON, Nov. 2, 2010 /PRNewswire/ -- QuantaLife, Inc. announced today at the 60th Annual American Society of Human Genetics Meeting the launch of their Droplet Digital™ PCR system. The system, which includes a droplet generator and a droplet reader, quantifies DNA molecules using the company's patented high-resolution, Droplet Digital PCR technology – a 3rd generation PCR technology that enables single-molecule resolution of target sequences.

Droplet Digital PCR uses microfluidics to partition each sample into 20,000 to millions of one-nanoliter droplets, each of which contains a separate PCR. The droplets are streamed in single file past a detector to count the negative and positive reactions.

The QuantaLife system introduces a new era of high performance PCR testing. The system detects slight differences in gene copy number (i.e., 6 copies from 5), or a 10% difference in mRNA expression. There is no need for a standard. The system can read 48 samples per hour.

Serge Saxonov, Ph.D, Vice President of Application Development at QuantaLife will present results obtained using the QuantaLife system at the ASHG meeting. The seminar titled "Introducing the 3rd Generation of PCR: droplet digital PCR – A New System for CNV Detection," will be held Friday, November 5, 2010 at 12:30 pm at the Grand Hyatt Washington, Lafayette Room, 1000 H Street NW, Washington, DC.

More information about QuantaLife and the Droplet Digital PCR system is available at www.quantalife.com.

About QuantaLife

QuantaLife has developed the 3rd generation of PCR technology that quantifies DNA molecules by Droplet Digital™ PCR . Droplet Digital PCR provides an absolute measure of target molecules with unrivaled quantitative resolution and sensitivity. Applications include copy number variation (CNV), mutation detection, and gene expression analysis. Our mission is to provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease.Contact:Mike LuceroQuantaLife, Inc.+1-650-823-6366
'/>"/>

SOURCE QuantaLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. QuantaLife, Inc. Unanimously Selected as the Most Promising Company at the Personalized Medicine World Conference 2010
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
(Date:3/22/2017)... March 22, 2017  UBM and the Massachusetts ... their extended partnership and the third annual Massachusetts Medtech ... the 21 st Annual MassMEDIC Conference held ... May 3-4, 2017. MassMEDIC will ... (ADVAMED) President and CEO, Scott Whitaker , ...
(Date:3/22/2017)... Mass. , March 22, 2017   iSpecimen ... today announced that Doctors Pathology Service (DPS), ... region of the United States , ... Delaware Health Information Network (DHIN) to make ... The novel program, announced in 2015 ...
(Date:3/22/2017)... - FACIT announced a seed stage investment in ... created by FACIT focused on developing a portfolio ... non-dilutive capital, achieves a targeted $3.0M financing for ... to accelerate the nomination of a candidate drug ... a strategic partnership for clinical trials in patients ...
Breaking Biology Technology:
(Date:2/27/2017)... Feb. 27, 2017   Strategic Cyber Ventures , ... has led a $3.5 million investment in  Polarity , ... Cyber Ventures is DC based and is led by ... Thomas . Ron Gula , also a longtime ... participated in this series A round of funding. This ...
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
Breaking Biology News(10 mins):